Logo image of TRIB

TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Fundamental Analysis

NASDAQ:TRIB - Nasdaq - US8964385046 - ADR - Currency: USD

0.731  -0.02 (-2.91%)

Premarket: 0.752 +0.02 (+2.87%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TRIB. TRIB was compared to 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TRIB have multiple concerns. TRIB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TRIB has reported negative net income.
TRIB had a negative operating cash flow in the past year.
TRIB had negative earnings in 4 of the past 5 years.
In multiple years TRIB reported negative operating cash flow during the last 5 years.
TRIB Yearly Net Income VS EBIT VS OCF VS FCFTRIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

TRIB's Return On Assets of -20.87% is in line compared to the rest of the industry. TRIB outperforms 52.15% of its industry peers.
Industry RankSector Rank
ROA -20.87%
ROE N/A
ROIC N/A
ROA(3y)-28.07%
ROA(5y)-22.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRIB Yearly ROA, ROE, ROICTRIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K 1.5K

1.3 Margins

TRIB's Gross Margin of 35.74% is on the low side compared to the rest of the industry. TRIB is outperformed by 70.43% of its industry peers.
TRIB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.44%
GM growth 5Y-4.34%
TRIB Yearly Profit, Operating, Gross MarginsTRIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
TRIB has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, TRIB has more shares outstanding
Compared to 1 year ago, TRIB has a worse debt to assets ratio.
TRIB Yearly Shares OutstandingTRIB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
TRIB Yearly Total Debt VS Total AssetsTRIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.40, we must say that TRIB is in the distress zone and has some risk of bankruptcy.
TRIB's Altman-Z score of -0.40 is in line compared to the rest of the industry. TRIB outperforms 44.62% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.4
ROIC/WACCN/A
WACC9.88%
TRIB Yearly LT Debt VS Equity VS FCFTRIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

TRIB has a Current Ratio of 1.64. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
TRIB has a worse Current ratio (1.64) than 73.12% of its industry peers.
A Quick Ratio of 0.87 indicates that TRIB may have some problems paying its short term obligations.
TRIB has a worse Quick ratio (0.87) than 84.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 0.87
TRIB Yearly Current Assets VS Current LiabilitesTRIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

TRIB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.11%, which is quite impressive.
Looking at the last year, TRIB shows a decrease in Revenue. The Revenue has decreased by -0.01% in the last year.
TRIB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.15% yearly.
EPS 1Y (TTM)34.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.75%
Revenue 1Y (TTM)-0.01%
Revenue growth 3Y-17.71%
Revenue growth 5Y-10.15%
Sales Q2Q%3.24%

3.2 Future

Based on estimates for the next years, TRIB will show a small growth in Earnings Per Share. The EPS will grow by 5.36% on average per year.
TRIB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.95% yearly.
EPS Next Y-194.92%
EPS Next 2Y-23.51%
EPS Next 3Y5.36%
EPS Next 5YN/A
Revenue Next Year6.69%
Revenue Next 2Y8.4%
Revenue Next 3Y9.95%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TRIB Yearly Revenue VS EstimatesTRIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
TRIB Yearly EPS VS EstimatesTRIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRIB. In the last year negative earnings were reported.
Also next year TRIB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRIB Price Earnings VS Forward Price EarningsTRIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRIB Per share dataTRIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.51%
EPS Next 3Y5.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRIB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRINITY BIOTECH PLC-SPON ADR

NASDAQ:TRIB (2/28/2025, 8:18:36 PM)

Premarket: 0.752 +0.02 (+2.87%)

0.731

-0.02 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)N/A N/A
Inst Owners4.63%
Inst Owner Change-2.5%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.12M
Analysts85.71
Price TargetN/A
Short Float %11.17%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.4%
Min EPS beat(2)-7.69%
Max EPS beat(2)16.49%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.68%
Min Revenue beat(2)-9.97%
Max Revenue beat(2)-1.38%
Revenue beat(4)0
Avg Revenue beat(4)-8.38%
Min Revenue beat(4)-12.24%
Max Revenue beat(4)-1.38%
Revenue beat(8)1
Avg Revenue beat(8)-8.64%
Revenue beat(12)1
Avg Revenue beat(12)-16.66%
Revenue beat(16)4
Avg Revenue beat(16)-11.95%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS2.15
BVpS-0.96
TBVpS-2.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.74%
FCFM N/A
ROA(3y)-28.07%
ROA(5y)-22.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.44%
GM growth 5Y-4.34%
F-Score4
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 431.9%
Cap/Sales 13.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 0.87
Altman-Z -0.4
F-Score4
WACC9.88%
ROIC/WACCN/A
Cap/Depr(3y)241.7%
Cap/Depr(5y)259.74%
Cap/Sales(3y)8.34%
Cap/Sales(5y)9.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.75%
EPS Next Y-194.92%
EPS Next 2Y-23.51%
EPS Next 3Y5.36%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.01%
Revenue growth 3Y-17.71%
Revenue growth 5Y-10.15%
Sales Q2Q%3.24%
Revenue Next Year6.69%
Revenue Next 2Y8.4%
Revenue Next 3Y9.95%
Revenue Next 5YN/A
EBIT growth 1Y27.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-256.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-357.13%
OCF growth 3YN/A
OCF growth 5YN/A